Senzime AB (publ)

OTCPK:SNZZ.F Stock Report

Market Cap: US$75.6m

Senzime Valuation

Is SNZZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNZZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$0.12
Fair Value
353.5% overvalued intrinsic discount
2
Number of Analysts

Below Fair Value: SNZZ.F ($0.53) is trading above our estimate of fair value ($0.12)

Significantly Below Fair Value: SNZZ.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNZZ.F?

Key metric: As SNZZ.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SNZZ.F. This is calculated by dividing SNZZ.F's market cap by their current revenue.
What is SNZZ.F's PS Ratio?
PS Ratio15.2x
SalesSEK 55.29m
Market CapSEK 842.54m

Price to Sales Ratio vs Peers

How does SNZZ.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SNZZ.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
HYPR Hyperfine
5.4x20.9%US$71.3m
ECOR electroCore
4.7x24.9%US$110.8m
ZOM Zomedica
5.1x25.2%US$135.4m
LUCD Lucid Diagnostics
11.4x44.1%US$47.7m
SNZZ.F Senzime
15.2x71.8%US$842.5m

Price-To-Sales vs Peers: SNZZ.F is expensive based on its Price-To-Sales Ratio (15.2x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does SNZZ.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

49 CompaniesPrice / SalesEstimated GrowthMarket Cap
VREX Varex Imaging
0.7x2.3%US$569.15m
INGN Inogen
0.7x4.4%US$231.51m
ARAY Accuray
0.5x5.5%US$214.20m
NVRO Nevro
0.3x2.9%US$130.78m
SNZZ.F 15.2xIndustry Avg. 3.4xNo. of Companies49PS03.26.49.612.816+
49 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SNZZ.F is expensive based on its Price-To-Sales Ratio (15.2x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is SNZZ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNZZ.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SNZZ.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNZZ.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.53
US$1.10
+109.0%
2.0%US$1.12US$1.08n/a2
Jan ’26US$0.53
US$1.13
+114.3%
2.0%US$1.15US$1.11n/a2
Dec ’25n/a
US$1.13
0%
2.0%US$1.15US$1.11n/a2
Nov ’25US$0.59
US$1.15
+94.6%
2.0%US$1.17US$1.12n/a2
Oct ’25n/a
US$1.21
0%
2.0%US$1.24US$1.19n/a2
Analyst Price Target
Consensus Narrative from 2 Analysts
US$1.02
Fair Value
48.1% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:34
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Senzime AB (publ) is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PalinCarnegie Commissioned Research
Oscar StjerngrenDanske Bank
Klas PalinPenser Access